TITLE: Integrating Prescription Drugs into Medicare

CIS-NO: 2002-H781-25  
SOURCE: Committee on Ways and Means. House  
DOC-TYPE: Hearing Retrieve the full text of testimony  
DATE: Apr. 17, 2002  
LENGTH: iii+122 p.  
CONG-SESS: 107-2  
ITEM-NO: 1028-A; 1028-B  
SUDOC: Y4.W36:107-65  
 
GPO-STOCK-NO: 552-070-28472-9.

SUMMARY:
Committee Serial No. 107-65. Hearing to examine proposals for Medicare reform, focusing on proposals to establish an outpatient prescription drug benefit for Medicare beneficiaries (Committee advisories, p. 2-4).
 
Supplementary material (p. 116-122) includes submitted statements.

CONTENT-NOTATION: Medicare prescription drug benefit, proposals review

DESCRIPTORS:  
    MEDICARE; DRUGS; MEDICAL REGULATION; MANAGED HEALTH CARE

02-H781-25 TESTIMONY NO: 1     Apr. 17, 2002 p. 13-59
 
WITNESSES (and witness notations):
   THOMPSON, TOMMY G. (Secretary, HHS)
 
STATEMENT AND DISCUSSION:
   Overview of Administration Medicare reform proposal, including proposed prescription drug coverage; views on Administration approach to strengthening Medicare program, including establishment of prescription drug coverage.
 
CONTENT NOTATION:
   Medicare prescription drug benefit, proposals review
 
TESTIMONY DESCRIPTORS:
   DEPARTMENT OF HEALTH AND HUMAN SERVICES
 
 
02-H781-25 TESTIMONY NO: 2     Apr. 17, 2002 p. 60-75
 
WITNESSES (and witness notations):
   WALKER, DAVID M. (Comptroller General, GAO)
 
STATEMENT AND DISCUSSION:
   Review of options to increase Medicare beneficiaries' access to prescription drugs.
 
CONTENT NOTATION:
   Medicare prescription drug benefit, proposals review
 
TESTIMONY DESCRIPTORS:
   GENERAL ACCOUNTING OFFICE
 
 
02-H781-25 TESTIMONY NO: 3     Apr. 17, 2002 p. 75-115
 
WITNESSES (and witness notations):
   BRADLEY, BRUCE E. (Director, Health Plan Strategy and Public Policy, General Motors Corp)
   GILMARTIN, RAYMOND V. (Chairman, President, and CEO, Merck and Co)
   NOVELLI, WILLIAM D. (Executive Director and CEO, AARP)
   RECTOR, JOHN M. (Senior Vice President, Government Affairs, National Community Pharmacists Association)
   SAYARE, MITCHEL (President, CEO, and Chairman, ImmunoGen, Inc.; representing Biotechnology Industry Organization)
 
STATEMENTS AND DISCUSSION:
   Views on and recommendations regarding Medicare prescription drug benefit coverage; perspectives of pharmacists on Medicare prescription drug benefit proposals; views of biotechnology industry on Medicare prescription drug coverage issues.
 
CONTENT NOTATION:
   Medicare prescription drug benefit, proposals review
 
TESTIMONY DESCRIPTORS:
   GENERAL MOTORS CORP.; MERCK AND CO.; AARP; NATIONAL COMMUNITY PHARMACISTS ASSOCIATION; BIOTECHNOLOGY INDUSTRY ORGANIZATION; PHARMACISTS AND PHARMACY; BIOTECHNOLOGY

LOAD-DATE: February 3, 2003